Skip Navigation


Annals of Oncology Advance Access originally published online on June 16, 2006
Annals of Oncology 2006 17(8):1301-1305; doi:10.1093/annonc/mdl108
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/8/1301    most recent
mdl108v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by McTiernan, A.
Right arrow Articles by Whelan, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McTiernan, A.
Right arrow Articles by Whelan, J. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumours

A. McTiernan, D. Driver, M. P. Michelagnoli, A. M. Kilby and J. S. Whelan*

Department of Oncology, UCL Hospitals NHS Foundation Trust, London, UK

* Correspondence to: Dr J. S. Whelan, The Department of Oncology, 1st Floor Central, UCL Hospitals NHS Foundation Trust, 250 Euston Road, London NW1 2BU, UK. Tel: +44 207 380 9346; Fax: +44 207 380 6952; E-mail: jeremy.whelan{at}uclh.org

Background: The outcome for patients with recurrent or progressive Ewing's sarcoma family of tumours (ESFT) is poor. High dose therapy (HDT) has been used for a number of years in an attempt to improve survival; however, evidence for the efficacy of this treatment remains limited.

Patients and methods: Between 1992 and 2004, 33 patients with recurrent or progressive ESFT were treated with HDT with bone marrow (n = 2), peripheral blood stem cell (n = 30), or bone marrow and peripheral blood stem cell support (n = 1), at a single institution. HDT was with busulphan and melphalan in 22 patients; melphalan and etoposide in seven patients, three with total body irradiation (TBI); melphalan in three patients (2 with TBI), and busulphan and cyclophosphamide in one patient.

Results: The 2 and 5 year event free survival was 42.5% (95% CI, 26–59%) and 38.2% (95% CI, 21–55%) respectively. There was one treatment related death from colitis, and grade 4 infection was observed in two patients.

Conclusions: Long-term survival can be attained in patients with recurrent or refractory ESFT treated with HDT. However, this treatment is associated with severe toxicity. A need remains for prospective randomised clinical trials of HDT in this group of patients.

Key words: Ewing's sarcoma, high dose therapy, PNET


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
K. Kikuta, N. Tochigi, T. Shimoda, H. Yabe, H. Morioka, Y. Toyama, A. Hosono, Y. Beppu, A. Kawai, S. Hirohashi, et al.
Nucleophosmin as a Candidate Prognostic Biomarker of Ewing's Sarcoma Revealed by Proteomics
Clin. Cancer Res., April 15, 2009; 15(8): 2885 - 2894.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.